BRIEF-Bristol-Myers Squibb says U.S. FDA accepts for priority review the sBLA for Opdivo
October 21, 2016 at 14:25 PM EDT
* U.S. Food and Drug Administration accepts for priority review the supplemental biologics license application for Opdivo (nivolumab) in previously treated patients with advanced form of bladder cancer